FDA Clears AI-Powered Module for Detecting Hemispheric Subdural Hematomas on CT
The Rapid SDH module on the RapidAI platform reportedly offers a sensitivity rate of 93 percent for detection of hemispheric subdural hematoma on non-contrast computed tomography (CT) scans.
The Food and Drug Administration (FDA) has granted 510(k) clearance for RapidAI’s Rapid SDH, an artificial intelligence (AI)-enabled module that reportedly notifies radiologists of suspected hemispheric subdural hematomas within one minute of reviewing a computed tomography (CT) scan.
For suspected acute and chronic hemispheric subdural hematomas > 1 mL, the Rapid SDH module offers a sensitivity rate of 93 percent and a specificity rate of 99 percent, according to RapidAI.
In addition to flagging suspected cases of hemispheric subdural hematomas, RapidAI said the Rapid SDH module facilitates multidisciplinary collaboration for the management of these patients via automated notification sent via the RapidAI app, PACS and e-mail.
"The FDA's clearance of Rapid SDH significantly enhances our expanding range of hemorrhagic and trauma care solutions at this crucial time of rapidly growing patient numbers, clinician shortages, and advancements in potential treatment options,” said Amit Phadnis, the chief innovation and technology officer of RapidAI. “Our goal is to continue to expand the capabilities and applications of our deep AI to deliver comprehensive clinical solutions that provide care teams with the crucial insights necessary to evaluate patients, streamline decision making, and expedite care for this common and dangerous disease.”
Recent Videos
Related Content
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Article
Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025Article
The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025Article
The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
